5:20 PM
 | 
Jan 29, 2019
 |  BC Extra  |  Company News

Spinraza sales lift Biogen revenues

Biogen Inc. (NASDAQ:BIIB) said Tuesday that growing sales of spinal muscular atrophy therapy Spinraza nusinersen helped the company to a 10% increase in 2018 revenues. The company also disclosed plans in its 2018 earnings to conduct a Phase III trial to evaluate if early use of aducanumab (BIIB037) can prevent or delay clinical onset of Alzheimer's disease.

Spinraza generated $470 million in 4Q18 sales,...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >